Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Candel Therapeutics, Inc.CADL · Entity 4969 | Chief Financial Officer | January 26, 2026 | January 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Candel Therapeutics, Inc.
Report date January 26, 2026 · Filed January 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.01 · Expires 2036-01-26 | Direct | 232,000 |
Reported balance
After 2026-01-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-26 · Grant · Acquired 232,000 · Balance 232,000 F1: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 26, 2026, subject to the Reporting Person's continued service on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 26, 2026, subject to the Reporting Person's continued service on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 26, 2026 Filed Jan 28, 2026 17:02 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 232,000 | $0.00 Strike: $6.01 | $0.00 |
DisclosureSEC source: 0001193125-26-027406 · ownership.xml · derivative · entry 1 Schoch Charles · CIK 0002007349 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,000 Underlying: Common Stock · 232,000 shares Expires 2036-01-26 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 26, 2026, subject to the Reporting Person's continued service on each vesting date. Read SEC document |
| June 25, 2025 Filed Jun 26, 2025 08:30 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantCommon Stock | 5,353 | $4.67 | $24,998.51 |
DisclosureSEC source: 0000950170-25-090193 · ownership.xml · nonDerivative · entry 1 Schoch Charles · CIK 0002007349 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,391 F1 · kind: Represents shares acquired from the Issuer in a registered direct offering pursuant to the terms of a Securities Purchase Agreement dated as of June 23, 2025. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 16:30 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0000950170-25-089473 · ownership.xml · derivative · entry 1 Schoch Charles · CIK 0002007349 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-06-20 F1 · derivative.exercise_date: This option is subject to time-based vesting. 25% of the shares underlying this option shall vest and become exercisable on June 20, 2026, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 16:06 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | SaleCommon Stock | 5,000 | $8.83 | $44,169.00 |
DisclosureSEC source: 0000950170-25-041991 · ownership.xml · nonDerivative · entry 1 Schoch Charles · CIK 0002007349 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,038 F1 · kind: This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/15/2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.74 to $8.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 herein. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 16:30 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 83,000 | $0.00 Strike: $8.55 | $0.00 |
DisclosureSEC source: 0000950170-25-021287 · ownership.xml · derivative · entry 1 Schoch Charles · CIK 0002007349 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,000 Underlying: Common Stock · 83,000 shares Expires 2035-02-12 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following February 12, 2025, subject to the Reporting Person's continued service on each vesting date. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 16:30 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | SaleCommon Stock | 9,511 | $7.23 | $68,716.98 |
DisclosureSEC source: 0000950170-25-006725 · ownership.xml · nonDerivative · entry 1 Schoch Charles · CIK 0002007349 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,038 F1 · shares: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units pursuant to the Issuer's mandatory sell to cover policy, which requires sales in an amount sufficient to cover tax withholding obligations associated with the vesting events, and the sales do not represent discretionary sales by the Reporting Person. Read SEC document |
| January 08, 2025 Filed Jan 10, 2025 16:30 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | SaleCommon Stock | 9,971 | $8.22 | $81,943.67 |
DisclosureSEC source: 0000950170-25-004199 · ownership.xml · nonDerivative · entry 1 Schoch Charles · CIK 0002007349 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,549 F1 · shares: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units pursuant to the Issuer's mandatory sell to cover policy, which requires sales in an amount sufficient to cover tax withholding obligations associated with the vesting events, and the sales do not represent discretionary sales by the Reporting Person. Read SEC document |
| July 17, 2024 Filed Jul 19, 2024 08:28 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | SaleCommon Stock | 9,884 | $6.47 | $63,975.18 |
DisclosureSEC source: 0000950170-24-084760 · ownership.xml · nonDerivative · entry 1 Schoch Charles · CIK 0002007349 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,520 F1 · shares: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units pursuant to the Issuer's mandatory sell to cover policy, which requires sales in an amount sufficient to cover tax withholding obligations associated with the vesting events, and the sales do not represent discretionary sales by the Reporting Person. Read SEC document |
| July 11, 2024 Filed Jul 15, 2024 08:34 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | SaleCommon Stock | 8,897 | $5.97 | $53,145.34 |
DisclosureSEC source: 0000950170-24-083399 · ownership.xml · nonDerivative · entry 1 Schoch Charles · CIK 0002007349 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,404 F1 · shares: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units pursuant to the Issuer's mandatory sell to cover policy, which requires sales in an amount sufficient to cover tax withholding obligations associated with the vesting events, and the sales do not represent discretionary sales by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.